Shots:
Medison & Albireo expands its collaboration to a multi-regional agreement to commercialize Odevixibat in Canada and Israel for the treatment of rare cholestatic liver diseases
The collaboration helps to enhance Albireo’s global commercial strategy and increases access to new markets for its innovative treatment. The collaboration also provides innovative solutions to patients suffering from rare cholestatic liver diseases
Odevixibat has been approved in the EU as Bylvay for the treatment of all types of PFIC in patients aged ≥6mos. Additionally, Bylvay has been approved in the US for the treatment of pruritus in patients aged ≥3mos. with all types of PFIC
Ref: PR Newswire | Image: Medison Pharma
